Stocks · Health care · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

REPL Clue Score21

United States Fiscal year ends March CIK 0001737953 Results filed 28 Oct 2026

Add to watchlist

By person

7 insiders · 1 transaction

19.2×

Sushil Patel holds 19.2 times base salary in stock. $13.45M of shares against $700.00K in salary for 2026.

Salary from the company's own proxy. The shares are what Sushil Patel last reported holding, valued at $19.00, the price Common Stock was last bought or sold at on the open market here, on 2 Nov 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Kapil Dhingra

Director

—

$408.50K (1) scheduled

−$408.50K

21,669

0.0258%

$411.71K

—

Philip Astley-Sparke

Director

—

1,362,414

1.62%

$25.89M

−5.2%

Sushil Patel

Chief Executive Officer

—

708,151

0.8436%

$13.45M

+234.0%

Konstantinos Xynos

Chief Medical Officer

—

224,215

0.2671%

$4.26M

+91.4%

Emily Luisa Hill

Chief Financial Officer

—

215,852

0.2571%

$4.10M

+113.6%

Christopher Sarchi

Chief Commercial Officer

—

180,962

0.2156%

$3.44M

+96.2%

Andrew Schwendenman

Chief Accounting Officer

—

99,425

0.1184%

$1.89M

−44.2%

Replimune Group, Inc.

What the insiders did Scheduled selling only

By person